Greenskeeper Asset Management, an independent firm that specializes in disciplined value investing, recently released its Q1 2026 scorecard. A copy is available to download here. The Middle East conflict triggered a sharp stock sell-off in the market, resulting in the Greenskeeper Value Fund posting a -8.1% return in Q1. Despite this challenging quarter, the fund took the opportunity to reinforce its portfolio. Please review the Fund’s top five holdings to gain insights into their key selections for 2026.
In its first-quarter 2026 investor letter, Greenskeeper Asset Management highlighted stocks like ICON Public Limited Company (NASDAQ:ICLR). ICON Public Limited Company (NASDAQ:ICLR) is a clinical research organization that provides outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. On June 12, 2026, ICON Public Limited Company (NASDAQ:ICLR) stock closed at $146.18 per share. One-month return of ICON Public Limited Company (NASDAQ:ICLR) was 28.48%, and its shares lost 0.58% over the past 52 weeks. ICON Public Limited Company (NASDAQ:ICLR) has a market capitalization of about $11.19 billion.
Greenskeeper Asset Management stated the following regarding ICON Public Limited Company (NASDAQ:ICLR) in its Q1 2026 investor letter:
“ICON Public Limited Company (NASDAQ:ICLR) -39.3% was our primary detractor this quarter following the February announcement of an internal Audit Committee investigation into revenue recognition practices from 2023 through 2025. While the market’s reaction was severe, we believe it was an overreaction. Management anticipates the revenue restatement will be less than 2% for each affected year. While disappointing, we believe this issue was an internal matter and will not have any material long-term impact on ICLR’s ability to serve its customers. It is also unlikely to have a material impact on the company’s $1 billion of free cash flow. We used the selloff as an opportunity to increase our position, and the stock has already begun to rebound. As the pharmaceutical environment continues to improve, we remain confident that the company will capture its fair share of clinical trial activity. With the stock trading at roughly 10x trailing earnings, we believe that the shares remain materially undervalued.”
ICON Public Limited Company (NASDAQ:ICLR) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 49 hedge fund portfolios held ICON Public Limited Company (NASDAQ:ICLR) at the end of the first quarter, up from 41 in the previous quarter. While we acknowledge the risk and potential of ICON Public Limited Company (NASDAQ:ICLR) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ICON PUBLIC LIMITED COMPANY (NASDAQ:ICLR) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered ICON Public Limited Company (NASDAQ:ICLR) and shared McIntyre Partnerships’ insights on the company. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
